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Abstract
Background: Early and late onset post-stroke cognitive impairment (PCI) contributes substantially to disability
following stroke, and is a high priority within stroke research. The aetiology for PCI is complex and related to the
stroke itself, brain resilience, comorbid brain diseases, prestroke vulnerability and complications during the hospital
stay. The aim of the Norwegian Cognitive Impairment After Stroke study (Nor-COAST) is to quantify and measure
levels of cognitive impairments in a general Norwegian stroke population and to identify biological and clinical
markers associated with prognosis for cognitive disorders following incident stroke. The study will be organised
within five work packages: 1) Incidence and trajectories 2) Pathological mechanisms 3) Development of a risk score
4) Impact of physical activity and 5) Adherence to secondary prevention.
Methods: Nor-COAST is an ongoing multicentre (five participating hospitals), prospective, cohort study with
consecutive inclusion during the acute phase and with follow-up at three and 18 months, and at three years.
Inclusion criteria are stroke defined according to the WHO criteria. During the recruitment period from 18.05.2015
to 31.03.2017, 816 participants have been included. Cognitive impairment will be classified according to the DSM-5
criteria using a consensus group. Cognitive function is assessed by a standardised neuropsychological test battery,
the Montreal Cognitive Assessment, Trail making A and B, ten-word immediate and delayed recall test, the
Controlled Oral Word Association, Global Deterioration Scale and proxy based information by and the Ascertain
Dementia 8 item informant questionnaire. Biomarkers include magnetic resonance imaging, routine blood samples
and bio-banking. Clinical assessments include characteristics of the stroke, comorbidity, delirium, frailty and tests for
cognitive and physical function, sensor based activity monitoring and adherence to secondary prophylaxis.
Discussion: Nor-COAST is the first Norwegian multicentre study to quantify burden of PCI that will provide reliable
estimates in a general stroke population. A multidisciplinary approach aiming to identify biomarkers and clinical
markers of overall prognosis will add new knowledge about risk profiles, including pre-stroke vulnerability and
modifiable factors such as physical activity and secondary prophylaxis of relevance for clinical practice and later
intervention studies.
Trial registration: ClinicalTrials.gov: NCT02650531. Retrospectively registered January 8, 2016. First participant
included May 18, 2015.
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Background
Stroke and cognitive impairment are common in old age.
One in three persons will develop stroke, dementia or
both [1], and the two conditions commonly coexist [2].
Impaired cognitive function contributes to the disability
following stroke [3] and affects both the individual and
the family and caregivers. With increased longevity and
ageing population, stroke and dementia will constitute a
substantial part of the disease burden in the years to come
[4] with a potentially large socioeconomic gain when im-
proving treatment and preventive strategies.
Cognitive function is therefore defined as a top prior-
ity for stroke research, especially studies of the links be-
tween cerebrovascular and degenerative disease are
requested [5–7]. The term post-stroke cognitive impair-
ment (PCI) is used to describe both mild cognitive im-
pairment (MCI) and dementia that either become
manifest three to six months after incident stroke (ear-
ly-onset PCI) or develops over months and years
(late-onset PCI). The observed delayed and accelerated
decline in cognitive function after incident stroke sug-
gest there is a therapeutic window for intervention and
prevention of PCI [7]. Identification of biomarkers and
clinical markers for risk of progression of PCI, could im-
prove our understanding of the underlying pathological
processes and help develop new strategies to reduce the
burden of PCI.
Incidence and trajectories of PCI
Reported rates for PCI varies considerably between stud-
ies. Many studies reports dementia but not MCI, and in
studies that include MCI the operational definition has a
large impact on the reported rate [8]. Pooled dementia
rates suggest that 10% of first ever stroke survivors de-
velop incident dementia within the first year, and 30%
after recurrent stroke [9]. A Norwegian study reported an
incidence of MCI and dementia one year after first ever
stroke of 37.5 and 19.6%, respectively [10]. Heterogenity
in reported rates of cognitive impairment following stroke
can be explained by casemix differences resulting from
population selection and attrition bias [6] and by varying
assessment time and tools, operational definitions and
diagnostic criteria [8]. Further there are few studies on the
course of PCI, especially of late-onset PCI, and it is
hypothesised that the course of PCI strongly depends on
the underlying mechanisms [11–14]. To quantify the over-
all burden of PCI and explore distinct trajectories and
their determinants, larger inclusive studies with longer
follow-up are warranted.
Biomarkers and predictors of PCI
A complex interplay of vascular pathology, neurodegen-
erative and inflammatory processes contributes to the
progression of PCI [11, 14–16]. Cognitive impairment
predisposes to stroke [15, 16] and patients with demen-
tia get more severe strokes [17], supporting that the two
conditions are related. Several imaging characteristics as-
sociated with PCI have been identified. Some imaging
findings are more extensively studied, especially the rela-
tionship between white matter hyperintensities and cog-
nitive impairment [18]. However, recently there has been
more attention on the association between degenerative
and vascular changes in the brain [2]. Chronic inflam-
mation seems to be involved in the pathogenesis of both
cerebrovascular disorders and Alzheimer’s disease. Im-
mune activation and immune depression are present in
the acute, sub-acute and chronic stage after a stroke and
diminished or impaired inflammatory mechanisms are
likely to be important factors in the pathways leading to
dementia [19]. Cytokines are potential drivers in
addition to neurovascular dysfunction, endothelial acti-
vation [20, 21] and genetic risk including Apolipoprotein
Eε4 (APOE ε4) carrier status [22]. Several clinical
markers are predictors of PCI, and the risk appears to
increase with increasing number of predictors. Predic-
tors include age, pre-stroke cognitive impairment,
pre-stroke functioning and frailty as well as characteris-
tics of the stroke lesion. In addition, complications in
the acute and sub-acute phase as delirium, infections,
falls and seizures seem to increase the risk [6].
Early and late-onset PCI is probably driven by some-
what different mechanisms, with brain resilience and
characteristics of the stroke lesion being the dominant
driver for early-onset PCI, while small vessel disease,
Alzheimer pathology and recurrent strokes are more
pronounced in late-onset PCI [11, 14, 23, 24].
Secondary prevention, adherence and physical activity
Prevention of recurrent strokes is important in prevent-
ing PCI [6] and can probably be achieved in up to 80%
by optimal secondary prevention [25]. A multi domain
intervention including vascular risk monitoring and
physical activity has shown to prevent cognitive decline
in at-risk stroke free elderly people suggesting that sec-
ondary prevention could have an additional and inde-
pendent effect on cognition and overall brain health
[26]. However, guidelines for secondary prevention are
rather complex, involving secondary preventive medica-
tions and healthy lifestyle including smoking cessation,
moderate alcohol consumption, healthy diet and regular
physical activity [27]. Adherence to both medication and
lifestyle interventions have been reported to be subopti-
mal in many patients [28], and adherence to secondary
prevention may be problematic in patients with cogni-
tive impairment after stroke.
There is evidence that physical activity enhances cog-
nitive function after stroke [29], and especially executive
function in individuals with MCI [30]. A recent
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meta-analysis, representing data from 736 participants
included in 14 randomized controlled trials, demon-
strated a significant positive effect of physical activity on
cognition post-stroke [31]. Possible mechanisms in-
volved are reduced levels of inflammation [32], improved
brain circulation, neurogenesis and increased size of
hippocampus [33, 34]. On the other hand, sedentary be-
haviour has been identified as a risk factor for vascular
disease, and hypothesized to increase the risk of cogni-
tive impairment after stroke [35].
Study aims
The aim of the Norwegian Cognitive Impairment After
Stroke study (Nor-COAST), is to quantify and measure
levels of cognitive impairments in a Norwegian general
stroke cohort and to identify biomarkers and clinical
markers associated with overall prognosis for early and
late onset PCI.
The Nor-COAST study is organised within five work
packages (WP). The aim of WP 1 is to describe inci-
dence and distinct trajectories of PCI. In WP 2, the aim
is to increase knowledge concerning the pathogenesis of
early and late-onset PCI by analysing brain imaging,
APOE ε4 typing and blood markers, and to explore asso-
ciations between neurodegenerative disease, underlying
vascular disease, inflammation and stroke characteristics.
In WP 3, we aim to identify predictors for PCI in order
to develop a novel risk score consisting of a few clinical
markers that will enable planning of individualized pre-
vention and treatment. The aim of WP 4 is to study the
impact of physical activity and sedentary behaviour on
PCI in the short and long term, and to explore associa-
tions between motor function measured by performance
based tests and progression of PCI. WP 5 aims to ex-
plore the impact of cognitive function on adherence to
secondary prevention and evaluate whether optimal sec-
ondary prophylaxis is protective against decline in cogni-
tive function over time Fig. 1.
Methods/design
The Nor-COAST study is a multicentre, prospective, co-
hort study following participants for three years from
the stroke incident. Recruitment started successively at
the different sites between 18.05.2015 and 01.09.2016
and was ended as preplanned 31.03.2017, with 816 par-
ticipants included. Participants were recruited from five
Norwegian stroke units at the following hospitals; St.
Olavs University Hospital, Trondheim (n = 400); Ålesund
Hospital, Møre and Romsdal Health Trust, Ålesund (n =
33), Haukeland University Hospital, Bergen (n = 142);
Bærum Hospital, Vestre Viken Hospital Trust, Drammen
(n = 142) and Oslo University Hospital, Ullevål, Oslo (n
= 99). All patients admitted to the participating
stroke-units were consecutively screened for eligibility
and approached as soon as the diagnosis was confirmed.
Informed consent was given prior to data collection by
the participant or by proxy if the participant lacked cap-
acity to give informed consent. All participants received
treatment and routine follow-up as usual in accordance
with national and international guidelines [36, 37].
Fig. 1 Nor-COAST is organised within five work packages (WP)
Thingstad et al. BMC Neurology          (2018) 18:193 Page 3 of 10
Sample size
Based on the Norwegian stroke registry we estimated
that about 1000 stroke patients in total would be avail-
able for inclusion per year in the participating hospitals.
Experience from earlier studies at the same hospitals in-
volved [10, 38] indicated that about half of eligible par-
ticipants would be included and that 20–25% would be
lost to follow-up during the data collection period of 18
months. With 750 patients available for follow-up, we
will be able to detect an association corresponding to a
correlation of 0.11 or higher (power 86% at significance
level 5%). Inclusion of approximately 1000 participants
would therefore be sufficient to answer the main re-
search questions within each work package. Based on
these assumptions we decided on a preplanned inclusion
stop at 1000 participants or a maximum of two years in-
clusion period.
Participants
Eligibility criteria are: 1) Admittance to one of the five
centres within seven days after symptom debut. 2) Acute
stroke diagnosed according to the World Health Organ-
isation (WHO) criteria or with findings of acute infarc-
tion or intra-cerebral haemorrhage on MRI. 3)
Scandinavian speaking 4) over > 18 years and 5) living in
the catchment area of the recruiting hospitals. Exclusion
criteria were expected survival less than three months.
Data collection and assessments
Assessments during the hospital stay are performed at
discharge or the seventh day of the stay for participants
with longer hospital stay. Study related follow-ups are
performed at the outpatient clinic three and 18 months,
and three years’ post-stroke. Participants unable to at-
tend the outpatient clinic are assessed by telephone
interview and/or proxy information is collected. Assess-
ments and interviews are performed by trained research
assistants, using a standardised paper Case Report Form
(CRF), and then plotted in web-based CRF developed by
the Unit for Applied Clinical Research, NTNU. Table 1
provides an overview of data collected by time and data
source.
Outcomes and measurements
Demographics, health history and disability
Sociodemographic characteristics are registered based
on medical records and interviews with patients and/or
caregivers. Information of health history, premorbid
function and life style habits are recorded using standar-
dised questionnaires from the Norwegian stroke registry
and the North-Trøndelag Health (HUNT) Study. Charl-
son comorbidity index identifies comorbidity, [39] and a
measure of frailty is achieved by the FRAIL scale [40].
The Modified Rankin Scale (mRS) evaluates the global
function, and instrumental activities of daily living
(I-ADL) is assessed by the Nottingham Extended ADL
scale [41] with the 4 subdomains of mobility, leisure time
activity, kitchen and domestic work. For basic ADL, the
Barthel Index [42] is used assessing independence in 10
basic ADL functions. Health related quality of life is
assessed using EQ-5D-5 L, [43] and fatigue by the
seven-item version of the Fatigue severity scale (FSS-7) [44].
Stroke characteristics, complications and medical treatment
Stroke symptoms and severity is assessed by National In-
stitutes of Health Stroke Scale (NIHSS). Strokes are clas-
sified according to the Oxfordshire Stroke Classification
Project (OSCP) [45] and the TOAST classification [46].
The confusion assessment method (CAM four item ver-
sion) for delirium evaluation is performed by the nurses
the first two days of hospital stay [47]. Acute treatment,
including thrombolysis and thrombectomies is obtained
from medical records. Use of medication at the time of
admission and at discharge is recorded based on infor-
mation from participants, proxies and medical records.
All drugs are classified by using the ATC-classification
system. Evaluation of the adherence to medication at
three and 18 months are based on self-reports according
to the 4-item Morisky Medication Adherence Scale
(MMAS-4) [48]. Follow-up routines in primary health
care will be investigated in a substudy.
Neuropsychological assessment
MCI and dementia are diagnosed according to the DSM-5
criteria [49], an expert panel will make consensus on how
to classify the cases. The neuropsychological test battery
in Nor-COAST is based on recommendations from the
National Institute of Neurological Disorders and Stroke-
Canadian Stroke Network (NINDS-CSN) using the
medium, 30min version [50], including Trail making A
and B (TMT A and B) [51], ten word memory and recall
test (CERAD) [52] and the controlled oral word associ-
ation test (COWAT) [53].
Screening of global cognitive function is performed
using the Montreal Cognitive Assessment (MoCA) [54].
MoCA evaluates several cognitive domains like memory,
visuospatial abilities, executive function, language, ab-
straction, attention, subtraction, digits forward and back-
ward and orientation and is also validated for telephone
interview [55]. Proxy based information on cognition is
collected using the Ascertain Dementia 8-item inform-
ant questionnaire (AD-8) [56]. The Global Deterioration
Scale (GDS) [57] measures global cognition and is
scored by the assessor, based on the combination of
available information from tests and interviews.
Neuropsyciatric Inventory (NPI-Q) [29] is a 12-item
questionnaire assessing occurrence and severity of ob-
served neuropsychiatric symptoms based on self-report or
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Table 1 Overview of assessments, source of data and time of assessment
T0: Baseline, T1: Three months follow-up, T2: 18 months
follow-up, T3: Three years follow-up
Medical records Examination Questionnaire Proxy T0 T1 T2 T3
Demographics x x ✓ ✓ ✓ ✓
Health history x x ✓ ✓ ✓ ✓
Medication x x x ✓ ✓ ✓ ✓
Magnetic Resonance Imaging x ✓ ✓ ✓
Clinical blood samples x ✓ ✓ ✓ ✓
Biobanking x ✓ ✓ ✓ ✓
Stroke characteristics
National Institute of Health Stroke Scale – NIHSS x ✓ ✓ ✓ ✓
Oxfordshire Stroke /TOAST classification x ✓
Activities of Daily Living (ADL)
Modified Rankin Scale (mRS) x x x ✓ ✓ ✓ ✓
Barthel Index x x x ✓ ✓ ✓ ✓
Nottingham E-ADL x x ✓ ✓ ✓ ✓
Cognitive function
Montreal Cognitive Assessment (MoCA) x ✓ ✓ ✓ ✓
Trail making Test A + B ✓ ✓ ✓ ✓
Ten-word immediate and delayed recall test (CERAD) x ✓ ✓ ✓
The Controlled Oral Word Association Test (COWAT) x ✓ ✓ ✓
Global Deterioration Scale (GDS) x x x ✓ ✓ ✓ ✓
The Ascertain Dementia 8-item Informant Questionnaire (AD8) x x ✓ ✓ ✓ ✓
The Confusion Assessment Method (4-item CAM) x ✓
Mental function
Hospital Anxiety and Depression Scale (HADS) x ✓ ✓ ✓
Cornell Scale for depression in Dementia x x ✓ ✓ ✓
Neuropsychiatric Inventory Questionnaire (NPI-Q) x x ✓ ✓ ✓
Line bisection neglect test x ✓ ✓ ✓ ✓
Health Related Quality of Life
EQ-5d-5 L x ✓ ✓ ✓
Physical function
Short Physical performance Battery (SPPB) x ✓ ✓ ✓ ✓
10m gait speed x ✓ ✓ ✓ ✓
Dual task gait (counting backwards) x ✓ ✓ ✓ ✓
360 degrees x ✓ ✓ ✓ ✓
One-leg stand x ✓ ✓ ✓ ✓
Nine-hole peg x ✓ ✓ ✓ ✓
Grip strength (Jamar) x ✓ ✓ ✓ ✓
Physical Activity
ActivPal (accelerometer) x ✓ ✓ ✓ ✓
Frailty
FRAIL Scale x ✓ ✓ ✓ ✓
Fatigue Severity Scale (FFS) x ✓ ✓ ✓
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proxy information. Symptoms of anxiety and depression
are screened for using Hospital Anxiety and Depression
Scale (HADS) [58] for self-reported symptoms. If the par-
ticipants are not able to respond, proxy information on
depression is collected by the Cornell scale [59].
Physical function and activity monitoring
Lower extremity function is measured by Short Physical
Performance Battery (SPPB) consisting of three subtasks:
4-m gait speed, balance and chair rise [60]. Additional
balance tests include one-leg-stance and 360* turning
[61]. Grip strength is measured by using a Jamar hand-
hold dynamometer. The nine-hole peg test is used to
measure dexterity [62]. Gait speed at preferred and fast
speed, and during dual task-performance (counting
backwards) are measured across 10 m with flying start.
Physical activity is measured using a three-axial accel-
erometer, ActivePAL monitors (PAL Technologies Ltd.,
Glasgow, United Kingdom), attached to the front of the
unaffected thigh during the hospital stay and for a mini-
mum of four days at three and 18 months’ and three
years’ follow-up. The inertial sensor produces a signal
related to thigh inclination and can thus identify posture
(sitting/lying from upright activity) [63]. This method is
shown to be valid in the stroke population [64].
Blood samples
Blood samples are analysed during the index stay and at
three and 18 months and three years for haemoglobin,
low density lipoprotein (LDL), high density lipoprotein
(HDL) and total cholesterol, glucose, glycosylated
haemoglobin (HbA1c), creatinine, high sensitive CRP
and troponin T. In addition, blood has been sampled in
BioBank 1, Central-Norway Regional Health Authority,
at baseline, three and 18months and three years for ana-
lyses regarding genetics and inflammation. If full blood
can not be sampled, saliva is collected in order to make
genetic analyses (APOE ε4 carrier status).
Neuroimaging
All patients undergo an acute CT scan to establish the
stroke diagnosis and the majority have a brain MRI scan as
part of routine diagnostic work-up. In addition, participants
are recruited for a study specific MRI brain scan within the
first 14 days after stroke. The MRI study protocol consists
of 3D-T1, axial T2, 3D-FLAIR, DWI and SWI sequences. A
follow-up scan with identical MRI protocol is performed
after 18months and at three years. Protocols were harmo-
nized between centres after scanning of the same healthy
volunteer and stroke volunteer in all scanners.
A standardized assessment of the MR findings in-
cludes systematically scoring for global atrophy, focal at-
rophy and vascular disease. For evaluation of white
matter hypertensities (WMH) we will use the Fazekas
scale [65]. For parietal atrophy we will use the posterior
atrophy scale [66]. Lacunes and cortical infarcts will be
registered and microbleeds will be assessed using the
Bombs scale [67]. Assessment of medial temporal lobe
atrophy (MTA) will be done using the Scheltens scale
[68]. We will follow the suggested STandards for Report-
Ing Vascular changes on nEuroimaging (STRIVE) [69].
Quantitative group analysis of the study specific MRI
with automated and semi-automated techniques will also
be performed.
National registries
Additional information on diagnosis, treatment, and
cause of death will be obtained from the Norwegian
Stroke Register, the Norwegian cardiovascular disease
registry, the Norwegian Prescription Database, the Nor-
wegian Patient Registry and the Norwegian cause of
death registry. Administrative permission to access data
from registries will be obtained within each workpackage
according to the specific research questions.
Statistical analysis
Demographics and participant characteristics will be
presented using descriptive statistics. Prevalence and in-
cidence of dementia will be presented by crosstabs. Stat-
istical analyses for trajectories will be performed with
group-based trajectory modelling, which uses maximum
likelihood to identify groups of individuals with statisti-
cally similar trajectories Two primary outputs of the es-
timations in group-based trajectory modelling are 1)
shapes of trajectories of each group as specified by
group-specific polynomial functions of time and 2) esti-
mated percentages of the population following each
identified trajectory [70]. Both results from visual and
volumetric brain analyses will be used to identify MRI
predictors of early or delayed of cognitive impairment
after stroke. Brain MRI analyses will be combined with
machine learning techniques to explore eventual clusters
in the study population and to build predictive models.
Network analysis with the “NetworkX” software package
[71]. is used to discover patient clusters. Predictive
models are build with classification algorithms like deci-
sion trees with “scikit-learn” [72]. and gradient boosting
with “XGBoost” [73]. Linear regression, logistic regres-
sion and other statistical methods will be used according
to the specific research questions within each work
package. A statistician is part of the project managing
group and will be involved in developing analysis plans
for the main publications and quality insurance of statis-
tical approach in each work package.
Discussion
The current paper describes the protocol of the
Nor-COAST study, an ongoing prospective, cohort study
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following 816 participants for three years after incident
stroke. This will be the first study to quantify and report
levels of cognitive impairment in a large Norwegian
stroke cohort. The study will focus on the diagnosis, in-
cidence and clinical entity of PCI, and provide estimates
for the burden of both early and late onset PCI in a gen-
eral stroke population.
The neuropsychological test battery used in the study
is sensitive to the mild cognitive impairments including
non-amnestic deficits [74] that are common in the
stroke population. This will be among the first studies to
use the DSM-5 criteria to diagnose MCI and dementia.
In contrast to the ICD-10 criteria, the DSM-5 criteria do
not require memory deficit for PCI diagnosis and are
consistent with the VASCOG criteria for diagnosing vas-
cular cognitive disorders [75] . Three years’ follow-up
will allow study of the mechanisms for late-onset PCI
for which there are currently few data.
Using registry data from the Norwegian stroke registry
allow us to account for some of the methodological chal-
lenges associated with bias, drop-outs and testability in a
heterogenic population [76–78]. This along with collec-
tion of proxy based information and systematic registra-
tions of reason for missing data should be an advantage
compared to many earlier studies aiming to describe the
overall burden of PCI.
By neuroimaging and identification of genetic, vascular
and inflammatory response-factors, we hope to achieve
insight of stroke as a trigger for degenerative brain pro-
cesses and the relevance of pre-existing risk factors, in-
cluding brain pathologies, for development of PCI. Both
results from visual and volumetric brain analyses will be
used to identify MRI predictors of early or late onset
cognitive impairment. The longitudinal design of
Nor-COAST enables us to look for the contribution of
vascular and degenerative changes to delayed onset PCI,
and to study the characteristics of patients with aug-
mented and prolonged inflammatory response.
We aim to develop a reliable and accurate tool to
identify patients at risk of developing PCI based on clin-
ical markers in early phase after stroke. This will provide
insight into the relative importance of patient vulnerabil-
ity in terms of frailty, comorbidity, pre-stroke function
and cognition, and the relation between cognitive out-
come and stroke and non-stroke factors such as location
and severity of stroke, specific treatment and complica-
tions including delirium. Further, we aim to explore
whether inclusion of biomarkers will increase the pre-
dictive value of the score. Identifying stroke survivors at
high risk at an early stage would enable early, personal-
ized and appropriate intervention for prevention.
Physical activity will be measured by use of body worn
sensors. This will make it possible to monitor physical
activity continuously for up to one week at inclusion and
at each follow-up, and thereby avoid some of the meth-
odological challenges, such as recall bias and overesti-
mation of activity, associated with the most commonly
used self-reported measures [79–82]. These data will
give the opportunity to investigate the underlying mech-
anisms of the possible preventive effect of physical activ-
ity or the negative effects of sedentary behaviour on
early and late onset of PCI. Identifying characteristics as-
sociated with sedentary behaviour could further help tar-
geting individuals who might benefit from closer
follow-up. Gait speed, lower extremity function, balance
and dexterity are assessed during the acute stay and at
each follow-up and will allow us to explore how different
aspects of motor function are associated with and pre-
dict PCI. There are studies indicating that screening of
motor function early after stroke might help identify in-
dividuals at risk of PCI [83], however, larger studies are
required.
The concept of adherence, will be assessed by combin-
ing information from subjective and objective sources.
With supplementary information and evaluation of
follow-up routines in primary health care, this sub-study
constitutes a valuable approach to a challenging and
sparsely studied research area where further data are
warranted [84, 85]. Secondary prevention is important
for the prognosis following a stroke, both because the
risk of PCI is strongly increased by a subsequent stroke,
but also because optimal treatment of vascular risk fac-
tors seem to impact neurodegeneration and small vessel
disease. The Nor-COAST study, collecting crucial data
for three years after a stroke, will give unique insight
into how PCI influences adherence to preventive mea-
sures and achievement of treatment goals and secondly
influences the risk of stroke and PCI.
The results of our comprehensive approach, combin-
ing assessment of biomarkers and clinical markers along
with modifiable factors including physical activity and
adherence, holds potential to reveal knowledge that
could inform routine clinical practice and be easily ap-
plicable in clinical practice. We aim to develop a tool for
the early identification of persons at risk and to improve
knowledge about modifiable factors such as physical ac-
tivity and secondary prophylaxis important for preven-
tion, treatment, rehabilitation and overall prognosis.
Increased knowledge of adherence to a healthy lifestyle
and pharmacological treatments will enable us to give
realistic and feasible individualised advice to prevent re-
current stroke and PCI.
Combination of biomarkers and clinical markers allow
us to explore the relationship between inflammation and
APOE status, chronic inflammation, sedentary behaviour,
stroke recurrence and cognition. Brain MRI analyses will
be combined with advanced statistical techniques to find
combinations of MRI findings and clinical variables
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associated with the development of PCI. The multidiscip-
linary approaches applied in the present study unite de-
mentia, geriatrics, stroke and physiotherapy research. This
gives us an opportunity to extend existing perspectives for
cooperation and to exploring the impact of for example
frailty and neurodegeneration on long-term outcome after
stroke.
There are some limitations of the Nor-COAST study.
Although the neuropsychological test battery contains
most of the cognitive domains in the DSM 5, symptoms
related to behavior and social cognition are not exten-
sively assessed. Further, some selection bias may have
occurred despite the inclusive nature of the study: po-
tential participants may not have been included because
of worse health status. Also the recommended neuro-
psychological battery is cited as taking up to 30min to
perform, but many patients needed longer or testing had
to be abandoned. In addition, some assessments, eg the
MRI study and parts of the cognitive testing, were not
feasible for all participants because of severe illness or
specific impairments.
Summary and conclusions
The Nor-COAST study will provide reliable estimates of
the burden of PCI in a general Norwegian stroke popu-
lation. Further, the study will add new and important
knowledge on the early detection of individuals at risk
for progression of PCI, extend understanding of the
underlying pathophysiology and the impact of pre-stroke
vulnerability, early physical activity and adherence to
secondary prevention on prognosis. The results will con-
tribute to the development of new guidelines for routine
clinical practice in stroke and better understanding of
mechanisms underlying PCI allowing the development
of more specific hypotheses and the design of future
intervention studies.
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